| |
PRZOOM - /newswire/ -
London, United Kingdom, 2009/02/16 - bioMérieux, a world leader in the field of in vitro diagnostics, offers a wide range of solutions to fight sepsis, the most common underlying cause of death in non-coronary intensive care units.
|
| |
This was illustrated by bioMérieux’s sponsoring of the Sepsis 2008 international symposium held in Spain last November.
Sepsis is a complex clinical syndrome that is defined as a systemic inflammatory response (SIRS) with presumed or confirmed bacterial infection (Source: Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ; Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis; The ACCP/SCCM Consensus Conference Committee; American College of Chest Physicians/Society of Critical Care Medicine; Chest. 1992; 101(6): 1644-55). The mortality rate in non-coronary intensive care units can be as high as 32% in cases of severe sepsis or 54% in cases of septic shock (Source: Vincent J-L, Sakr Y, Sprung CL, et al; Sepsis in European intensive care units: Results of the SOAP study; Crit Care Med 2006; 34: 344-355).
Early recognition and timely initiation of appropriate therapy is key to improving the outcome of patients with sepsis (Source: Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign guidelines for the management of severe sepsis and septic shock; Crit Care Med 2004; 32: 858-873). By rapidly and accurately detecting the presence of microbial infection in SIRS patients, in vitro diagnostic tests can provide clinically relevant information and support early diagnosis of sepsis.
For bioMérieux, an expert in diagnostic solutions for infectious disease management, sepsis is a key area. The company has developed a broad range of solutions to support clinical diagnosis, prognosis and antibiotic stewardship for the management of sepsis. bioMérieux’s aim is to lead the way as a partner to healthcare professionals around the world in the fight against sepsis.
bioMérieux’s products span microbiology, immunoassay and molecular biology technologies. The extensive range includes BacT/ALERT® for blood cultures, VIDAS® B.R.A.H.M.S PCT for early detection and monitoring of severe bacterial infections, VITEK® 2 for automated identification and antibiotic susceptibility testing, and Etest®, a predefined gradient technique used to determine the on-scale Minimum Inhibitory Concentration (MIC) of antibiotics agents. bioMérieux also distributes AdvanDx rapid molecular tests – PNA FISH® – in the United States for species identification of bacteria and yeast from positive blood cultures (a procedure that takes less than three hours).
bioMérieux has been a sponsor of the valuable work undertaken by the International Sepsis Forum (ISF) group for many years, and actively participated in Sepsis 2008, an international symposium held in Granada (Spain) from 19 to 22 November 2008.
About bioMérieux
A world leader in the field of in vitro diagnostics for 45 years, bioMérieux (biomerieux.com) is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2007, group revenues reached €1.063 billion, with 84% of sales generated outside France.
bioMérieux provides diagnostic solutions (reagents, instruments and software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting micro-organisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the NYSE Euronext Paris market (Code: BIM – Code ISIN: FR0010096479).
|
contact.ftpb[.]ubifrance.fr 
